Deployment
Cyberdyne HAL at United States
Powered (motor-driven) exoskeleton whose distinguishing feature is bioelectric-signal control: skin-surface sensors detect the faint nerve/muscle signals of intended movement and drive the actuators in sync. Medical lower-limb version FDA cleared 2017; clinical use in Japan since 2008.
Cyberdyne HAL by Cyberdyne · Catalog entry · 2 sources · not yet field-verified · Exoskeletons
Recent coverage
- Pegasus and CYBERDYNE launch 0M fund for physical AIBen Smith, Deploy Editor · 2025-01-01
Cyberdyne operates fee-based medical HAL services in the US through subsidiary RISE Healthcare Group at 5 Southern California locations. FDA clearance covers SCI, stroke, progressive neuromuscular diseases, and cerebral palsy (ages 12+). Carnegie Mellon University MOU signed December 2025 to accelerate US social implementation.
Key facts
- FDA status
- FDA cleared for SCI, stroke, 8 progressive neuromuscular diseases, cerebral palsy (ages 12+), HAM, hereditary spastic paraplegia
- US clinical sites
- RISE Healthcare Group operates 5 fee-based medical locations in Southern California
- CMU partnership
- Strategic MOU with Carnegie Mellon University signed December 2025 for US social implementation
Exposure
- Customer segment
- research
- Scale tier
- pilot lt10
Each exposure value carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Safety record
No incidents on record for Cyberdyne HAL at United States.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
- Trust tier
- Catalog entry · 2 sources · not yet field-verifiedhow tiers work →
- Last updated
- 2026-08-21
- Model
- Cyberdyne HAL
- Company
- Cyberdyne
- Location
- United States
- Operator
- Cyberdyne
- Status
- operational
- Operator type
- maker operated
- Scale at site
- 2 to 10 units
- Site environment
- indoor
- Location precision
- verified coordinates
- First seen
- 2024-06-01
- ID
0c08a628-e850-46cf-8942-fdf91fcc9e05
Timeline
- Jun 2024First recordedCyberdyne HAL first documented operating at United States.
- Jun 2026created
- Aug 2026Current status: operational, reviewedLatest recorded state. New status transitions append here as the deployment-status recorder produces them.
On the deployment map
Cyberdyne HAL operates in United States. Explore the full verified map:
Sources (2)
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-08-21
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-08-21
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: exoskeleton
Sources by quality tier
- 1
- unclassified
- Unclassified source
- 1
- primary-fda-database
- FDA database
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Cyberdyne HAL at United States.Common questions
What is the Cyberdyne HAL deployment at United States?
Who operates Cyberdyne HAL at United States?
When did the Cyberdyne HAL deployment at United States go live?
Have there been incidents at the Cyberdyne HAL deployment at United States?
Deploy Watch
Track this deployment.
We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.
Machine-readable surfaces
- Markdown mirror: /deployments/cyberdyne-hal-united-states.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/robots/0c08a628-e850-46cf-8942-fdf91fcc9e05
- Data documentation: /data
- Query this programmatically: Deploy MCP